Back to Search
Start Over
Albumin-Induced Neuroprotection in Focal Cerebral Ischemia in the ALIAS Trial: Does Severity, Mechanism, and Time of Infusion Matter?
- Source :
- Neurocritical Care. 28:60-64
- Publication Year :
- 2017
- Publisher :
- Springer Science and Business Media LLC, 2017.
-
Abstract
- To determine whether there is any differential benefit of albumin administration within 2 h of onset of ischemia and in settings (severe ischemia with reperfusion in cardioembolic strokes with National Institutes of Health Stroke Scale [NIHSS] ≥15), most representative of experimental models of cerebral ischemia in which albumin was effective in reducing neurological injury. High-dose intravenous (IV) albumin treatment for acute ischemic stroke (ALIAS) trial did not show overall clinical benefit in ischemic stroke patients in contrast to preclinical studies; however, models of preclinical studies were not completely followed. A total of 1275 patients combined from ALIAS trials I and II were included in our analysis. We analyzed preclinical studies and selected patients with large ischemic stroke (NIHSS ≥15) related to cardioembolic etiology (n = 189). Outcomes were then studied including time from onset to IV albumin administration. The odds of excellent outcome (mRS 0–1) at 3 months was not different with high-dose IV albumin infusion (n = 100) compared with placebo (n = 89) ((odds ratio [OR]) 1.632 [0.719–3.708], p value 0.2419). When we further classified these subjects according to time of IV albumin administration, we observed significantly higher odds of excellent outcome at 3 months when patients received IV albumin within 2 h, OR 9.369 (CI 1.040–84.405), p value 0.0461, after adjusting for age, gender, baseline NIHSS score, and any therapeutic procedure. A trend for benefit is noted in ischemic stroke patients with large cardioembolic stroke (NIHSS ≥15) when high-dose albumin was initiated within 2 h, suggesting that certain ischemic stroke subgroups of patients most representative of preclinical settings may benefit from such a treatment. Additional clinical trials maybe needed to stratify subjects and treatment assignments according to NIHSS severity and timely randomization to evaluate this concept further.
- Subjects :
- Male
medicine.medical_specialty
Time Factors
Randomization
Neurology
Heart Diseases
Embolism
Ischemia
Serum Albumin, Human
030204 cardiovascular system & hematology
Critical Care and Intensive Care Medicine
Placebo
Severity of Illness Index
Brain Ischemia
03 medical and health sciences
0302 clinical medicine
Internal medicine
Humans
Medicine
cardiovascular diseases
Infusions, Intravenous
Aged
Aged, 80 and over
business.industry
Albumin
Odds ratio
Middle Aged
medicine.disease
Neuroprotection
Stroke
Clinical trial
Outcome and Process Assessment, Health Care
Anesthesia
Cardiology
Etiology
Female
Neurology (clinical)
business
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 15560961 and 15416933
- Volume :
- 28
- Database :
- OpenAIRE
- Journal :
- Neurocritical Care
- Accession number :
- edsair.doi.dedup.....e94b971968198053a48d641450fb3893
- Full Text :
- https://doi.org/10.1007/s12028-017-0400-0